Journal: Scientific Reports

Article Title: Immunoregulation induced by autologous serum collected after acute exercise in obese men: a randomized cross-over trial

doi: 10.1038/s41598-020-78750-z

Figure Lengend Snippet: CD4 + and CD8+ T cells expressing PD-1 or CTLA-4 following in vitro incubation with autologous serum from before (white bars) and after (black bars) two types of exercise. The frequencies of CD4 + CTLA-4 + ( 4A ), CD4 + PD-1 + ( 4B ) and CD8 + PD-1 + ( 4C ) T cells were analyzed by flow cytometry after in vitro PBMC stimulation with serum collected before and immediately after high-intensity interval exercise (HIIE) or exhaustive exercise. Statistical analysis conducted by two-way repeated measurements ANOVA with Bonferroni’s post hoc ( p < 0.05).

Article Snippet: Briefly, 2 × 10 5 PBMCs were stained with monoclonal antibodies (all anti-human) conjugated with specific fluorochromes: CD4 FITC, CD8 PerCP, CD25 Pe, CD39 PerCP-7, CD73 APC (all from Ebioscience, USA); CD125 (CTLA-4) Pe, CD279 (PD-1) Pe (all from Biogems, USA).

Techniques: Expressing, In Vitro, Incubation, Flow Cytometry

Journal: World Journal of Gastroenterology : WJG

Article Title: Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells

doi: 10.3748/wjg.v16.i5.618

Figure Lengend Snippet: Programmed death type-1 (PD-1) expression in total peripheral CD8+ T cells in the natural stages of chronic hepatitis B virus (HBV) infection. A: The dot plots showing the percentage of PD-1+ CD8+ T cells in different natural stages of chronic HBV infection patients and normal controls and the horizontal bars indicating the median percentage of positive PD-1 in CD8+ T cells; B: The dot plots showing the PD-1 mean fluorescence intensity (MFI) expression in total CD8+ T cells, and the horizontal bars indicating the median PD-1 MFI expression level in CD8+ T cells. NC: Normal control.

Article Snippet: The PE-labeled anti-PD-1 monoclonal antibodies were obtained from BD PharMingen (BD Biosciences, San Jose, CA).

Techniques: Expressing, Infection, Fluorescence

Journal: World Journal of Gastroenterology : WJG

Article Title: Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells

doi: 10.3748/wjg.v16.i5.618

Figure Lengend Snippet: PD-1 expression levels in the total T cells in the immune clearance stage of chronic HBV infection and liver inflammatory groups. A: The dot plots showing the percentage of positive PD-1 in CD8+ T cells in high and low liver inflammatory groups; B: The dot plots showing the PD-1 MFI expression level in the total CD8+ T cells in high and low liver inflammatory groups; C: Positive correlation between PD-1 MFI expression and alanine aminotransferase (ALT) levels in CD8+ T cells; D: Positive PD-1 percentage and ALT level in CD8+ T cells.

Article Snippet: The PE-labeled anti-PD-1 monoclonal antibodies were obtained from BD PharMingen (BD Biosciences, San Jose, CA).

Techniques: Expressing, Infection

Journal: World Journal of Gastroenterology : WJG

Article Title: Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells

doi: 10.3748/wjg.v16.i5.618

Figure Lengend Snippet: Effect of anti-PD-L1 antibody on the function of CD8+ T cells in the immune clearance stage of chronic HBV infection. A, B: Significant restoration of CD8+ T cell response after blockage of PD-1/PD-L1; C: Restoration of T-cell proliferation after blockage of PD-1/PD-L1.

Article Snippet: The PE-labeled anti-PD-1 monoclonal antibodies were obtained from BD PharMingen (BD Biosciences, San Jose, CA).

Techniques: Infection

Journal: World Journal of Gastroenterology : WJG

Article Title: Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells

doi: 10.3748/wjg.v16.i5.618

Figure Lengend Snippet: Relation between PD-1 expression level in CD8+ T cells and CD8+ T-cell responses in the immune clearance stage of chronic HBV infection. A: Inverse relation between the percentage of perforin and PD-1 MFI in positive CD8+ T cells; B: Inverse relation between the percentage of granzyme B and PD-1 MFI in positive CD8+ T cells; C: No correlation between the percentages of granzyme B and PD-1 in positive CD8+ T cells; D: No significant correlation between the percentages of perforin and PD-1 in positive CD8+ T cells.

Article Snippet: The PE-labeled anti-PD-1 monoclonal antibodies were obtained from BD PharMingen (BD Biosciences, San Jose, CA).

Techniques: Expressing, Infection

Journal: ESMO Open

Article Title: Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer

doi: 10.1016/j.esmoop.2021.100094

Figure Lengend Snippet: Association between the activation states and cytotoxic effects of dicycloplatin (DCP) in peripheral blood mononuclear cells (PBMCs) stimulated by the anti-CD3 antibody (anti-CD3 Ab). (A, B) Proliferation of anti-CD3 Ab-stimulated PBMCs. Proliferation rate (day n ) = MFI (day n )/MFI (day n −1). (C, D) PD-1 expression in anti-CD3 Ab-stimulated PBMCs. Dynamic changes in (C) the positive percent of PD-1 expression compared to the isotype control, and (D) the MFI of PD-1 expression on CD3 + T cells after stimulation were detected by flow cytometry. (E, F) Cytotoxic effect of DCP in anti-CD3 Ab-stimulated PBMCs. PBMCs stimulated with the anti-CD3 Ab for different lengths of time were used to represent different activation states, and the cells were exposed to a full range of concentrations of DCP for 72 h before detection. (F) The 50% inhibitory concentration (IC 50 ) values of DCP in PBMCs stimulated for 2-6 days were compared with those in PBMCs stimulated for 1 day. The data are presented as mean ± SD of three independent experiments. ∗ P < 0.05, statistically significant. MFI, mean fluorescence intensity.

Article Snippet: The anti-PD-1-PE and PD-1 isotype antibodies were purchased from BD Pharmingen (San Diego, CA, USA).

Techniques: Activation Assay, Expressing, Flow Cytometry, Concentration Assay, Fluorescence

Journal: ESMO Open

Article Title: Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer

doi: 10.1016/j.esmoop.2021.100094

Figure Lengend Snippet: Impacts of the anti-PD-1 antibody (Ab) on cell proliferation and the cytotoxic effect of dicycloplatin (DCP) in peripheral blood mononuclear cells (PBMCs). (A) Effect of the anti-PD-1 Ab on anti-CD3 Ab-stimulated PBMCs. (B) Effect of the recombinant PD-L1 protein on anti-CD3 Ab-stimulated PBMCs. (C) Effect of the anti-PD-1 Ab on PD-L1-inhibited PBMCs. The recombinant PD-L1 protein and anti-PD-1 Ab were used at 2 μg/ml and 10 μg/ml, respectively, and cells were incubated for 6 days before detection. The graph shows a representative case from six sets of PBMCs, four of which demonstrated recovery from PD-L1-induced proliferation inhibition. (D) Effect of the anti-PD-1 Ab on the cytotoxicity of DCP in PD-L1-inhibited PBMCs. PBMCs pretreated with the PD-L1 protein (and anti-PD-1 Ab for the DCP + aPD-1 group) for 6 days were incubated with DCP for 72 h before detection. The graph shows the relative cytotoxicity of DCP at 1 μM. (E, F) Effect of the combined timing of anti-PD-1 Ab on the cytotoxicity of DCP in PD-L1-inhibited PBMCs. The cytotoxicity of DCP was measured by a (E) luminescent cell viability assay and (F) lactate dehydrogenase (LDH) assay. The relative cytotoxicity of DCP = [MFI (aPD-1) − MFI (DCP + aPD-1)]/MFI (aPD-1) for the cell viability assay. Each column indicates the mean ± SD of triplicate tests. ns, not statistically significant. ∗ P < 0.05, ∗∗ P < 0.01, statistically significant. ATP, adenosine triphosphate.

Article Snippet: The anti-PD-1-PE and PD-1 isotype antibodies were purchased from BD Pharmingen (San Diego, CA, USA).

Techniques: Recombinant, Incubation, Inhibition, Cell Viability Assay, Lactate Dehydrogenase Assay, Viability Assay

Journal: ESMO Open

Article Title: Impact of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy on the outcomes in patients with refractory lung cancer

doi: 10.1016/j.esmoop.2021.100094

Figure Lengend Snippet: Survival analyses. (A, B) Receiver operating characteristic (ROC) curve analyses of (A) overall survival and (B) progression-free survival for the optimal cut-off value of the combined timing of PD-1/PD-L1 inhibitors and chemotherapy. (C-F) Patient survival. Kaplan–Meier survival curves comparing overall survival and progression-free survival between different combined-timing groups. CI, confidence interval; HR, hazard ratio; mOS, median overall survival; mPFS, median progression-free survival.

Article Snippet: The anti-PD-1-PE and PD-1 isotype antibodies were purchased from BD Pharmingen (San Diego, CA, USA).

Techniques: